PDCOS
MCID: PDC001
MIFTS: 41

Podoconiosis (PDCOS)

Categories: Immune diseases

Aliases & Classifications for Podoconiosis

MalaCards integrated aliases for Podoconiosis:

Name: Podoconiosis 56 12 15 17 71
Podoconiosis, Susceptibility to 56 13
Nonfilarial Elephantiasis of Lower Legs, Susceptibility to 56
Endemic Nonfilarial Elephantiasis, Susceptibility to 56
Lymphostatic Verrucosis, Susceptibility to 56
Nonfilarial Elephantiasis of Lower Legs 56
Endemic Non-Filarial Elephantiasis 71
Endemic Nonfilarial Elephantiasis 56
Lymphostatic Verrucosis 56
Elephantiasis 43
Pdcos 56

Classifications:



External Ids:

Disease Ontology 12 DOID:0050138
OMIM 56 614590
MeSH 43 D004604
UMLS 71 C1280469 C3494152

Summaries for Podoconiosis

OMIM : 56 Podoconiosis, or endemic nonfilarial elephantiasis, is a noninfectious geochemical disease characterized by edema of the foot and lower leg that progresses to severe elephantiasis. It is a chronic and debilitating disorder that is a public health problem in at least 10 countries in tropical Africa, Central America, and northern India. Podoconiosis occurs among subsistence farmers and other occupational groups whose feet are exposed over many years to red clay soil derived from alkalic volcanic rock. However, podoconiosis develops only in a subgroup of exposed people, and studies have shown familial clustering with high heritability (summary by Davey et al. (2007) and Tekola Ayele et al. (2012)). (614590)

MalaCards based summary : Podoconiosis, also known as podoconiosis, susceptibility to, is related to loiasis and filarial elephantiasis. An important gene associated with Podoconiosis is PDCOS (Podoconiosis, Susceptibility To), and among its related pathways/superpathways are ICos-ICosL Pathway in T-Helper Cell and TCR signaling (REACTOME). The drugs Diethylcarbamazine and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include lower extremities, skin and testes.

Disease Ontology : 12 An elephantiasis that is characterized by lymphadema located in the lower extremities caused by a genetically determined abnormal inflammatory reaction to mineral particles in irritant red clay soils derived from volcanic deposits.

Wikipedia : 74 Podoconiosis, also known as nonfilarial elephantiasis, is a disease of the lymphatic vessels of the... more...

Related Diseases for Podoconiosis

Diseases related to Podoconiosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 loiasis 32.1 STH CNTD1
2 filarial elephantiasis 31.5 STH CNTD1
3 elephantiasis 30.6 TVP23C STH MAS1L CNTD1 CDRT4
4 onchocerciasis 30.1 STH HLA-DQA1 CNTD1
5 filariasis 10.7
6 hereditary lymphedema i 10.6
7 neurofibromatosis 10.5
8 erysipelas 10.4
9 leprosy 3 10.4
10 hansen's disease 10.4
11 yaws 10.4
12 lymphogranuloma venereum 10.3
13 congestive heart failure 10.3
14 neurofibroma 10.3
15 venous insufficiency 10.3
16 hydrocele 10.3
17 lymphangiosarcoma 10.3
18 cellulitis 10.3
19 leptin deficiency or dysfunction 10.2
20 chronic venous insufficiency 10.2
21 granuloma inguinale 10.2
22 skin disease 10.2
23 achalasia, familial esophageal 10.2 HLA-DQB1 HLA-DQA1
24 primary adrenal insufficiency 10.2 HLA-DQB1 HLA-DQA1
25 beryllium disease 10.2 HLA-DQB1 HLA-DQA1
26 kaposi sarcoma 10.2
27 myxedema 10.2
28 kala-azar 1 10.2
29 hidradenitis suppurativa 10.2
30 hidradenitis 10.2
31 leishmaniasis 10.2
32 congenital lymphedema 10.2
33 lymphangiectasis 10.2
34 autoimmune hepatitis type 1 10.2 HLA-DQB1 HLA-DQA1
35 focal epithelial hyperplasia 10.2 HLA-DQB1 HLA-DQA1
36 idiopathic bronchiectasis 10.1 HLA-DQB1 HLA-DQA1
37 oligoarticular juvenile idiopathic arthritis 10.1 HLA-DQB1 HLA-DQA1
38 angiosarcoma 10.1
39 dermatitis 10.1
40 congenital toxoplasmosis 10.1 HLA-DQB1 HLA-DQA1
41 proteus syndrome 10.1
42 deficiency anemia 10.1
43 trypanosomiasis 10.1
44 silicosis 10.1
45 miliaria rubra 10.1
46 trachoma 10.1
47 iron deficiency anemia 10.1
48 miliaria 10.1
49 lymphadenitis 10.1
50 keratosis 10.1

Graphical network of the top 20 diseases related to Podoconiosis:



Diseases related to Podoconiosis

Symptoms & Phenotypes for Podoconiosis

Clinical features from OMIM:

614590

Drugs & Therapeutics for Podoconiosis

Drugs for Podoconiosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 18)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Petrolatum Approved, Investigational Phase 3 8009-03-8
3
Glycerol Approved, Investigational Phase 3 56-81-5 753
4
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
5 Eusol Phase 3
6 Protective Agents Phase 3
7 Sodium hypochlorite Phase 3
8 Milbemycin Phase 3
9 Antimalarials Phase 3
10
Sodium citrate Approved, Investigational 68-04-2
11
Mebendazole Approved, Vet_approved 31431-39-7 4030
12
Piperazine Approved, Vet_approved 110-85-0 4837
13
Permethrin Approved, Investigational 52645-53-1 40326
14
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
15 Citrate
16 Piperazine citrate
17 DMP 777 157341-41-8
18 Liver Extracts

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Completed NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
3 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
4 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
5 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
6 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
7 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
8 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
9 A Clinical Trial to Assess the Safety and Efficacy of Moxidectin Combination Treatments vs. Ivermectin Combination Treatments for Bancroftian Filariasis Recruiting NCT04410406 Phase 3 IA (IVM+ ABZ);MoxA (Mox + ABZ);IDA (IVM + DEC + ABZ);MoxDA (Mox + DEC + ABZ)
10 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
11 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
12 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
13 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
14 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
15 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
16 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
17 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
18 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
19 Study on Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer Recruiting NCT03295526 Phase 2
20 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
21 Prevalence of Obstructive Sleep Apnea Syndrom in Patients With Lymphedema, Admitted for Intensive Decongestive Physiotherapy Unknown status NCT02979184
22 Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches Completed NCT01939431
23 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
24 Exhaled NO Testing in Filariasis Completed NCT01628497
25 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
26 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
27 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
28 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
29 Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators Completed NCT03352206 2 drug dose - DA;3 drug dose - IDA
30 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
31 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
32 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
33 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
34 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
35 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
36 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
37 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
38 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
39 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
40 Research for Elimination of Human Filariasis Completed NCT00145223
41 The Inter- and Intra-rater Reliability of Subcutaneous Echogenicity (SEG) Grade and Subcutaneous Echo-free Space (SEFS) Grade in Postmastectomy Lymphedema Completed NCT03559296
42 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Recruiting NCT03683745
43 When is it Appropriate to Stop? Applied Field Research to Develop an M&E Strategy to Recruiting NCT04124250
44 Effect of Filarial Infection on Antigen-Specific Immune Responses in Latent Tuberculosis Recruiting NCT01547884
45 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
46 Evaluation of Outcomes of Microvascular Breast Reconstruction With Lymph Node Transfer for Postmastectomy Lymphedema Patients Not yet recruiting NCT04246034
47 Spontaneous Antigenemia in Loiasis, A Study of the Loiasis Antigens Responsible for Cross-reactivity in the Rapid Diagnostic Test for Lymphatic Filariasis Suspended NCT04258670
48 Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi, Open Label Study Terminated NCT01213576 Albendazole 400mg and ivermectin 200mcg/kg;Albendazole and ivermectin;Albendazole 400mg and ivermectin 200mcg/kg;albendazole 800mg and ivermectin 400mcg/kg bi-annually

Search NIH Clinical Center for Podoconiosis

Cochrane evidence based reviews: elephantiasis

Genetic Tests for Podoconiosis

Anatomical Context for Podoconiosis

The Foundational Model of Anatomy Ontology organs/tissues related to Podoconiosis:

19
Lower Extremities

MalaCards organs/tissues related to Podoconiosis:

40
Skin, Testes, Lymph Node, Liver, Breast

Publications for Podoconiosis

Articles related to Podoconiosis:

(show top 50) (show all 164)
# Title Authors PMID Year
1
HLA class II locus and susceptibility to podoconiosis. 56 61
22455414 2012
2
Images in clinical medicine. Podoconiosis. 56 61
21428762 2011
3
Podoconiosis: a tropical model for gene-environment interactions? 56 61
16884751 2007
4
Pre-elephantiasic stage of endemic nonfilarial elephantiasis of lower legs: "podoconiosis". 61 56
6464174 1984
5
The association of endemic elephantiasis of the lower legs in East Africa with soil derived from volcanic rocks. 56
1006757 1976
6
A possible genetic factor in non-filarial elephantiasis of the lower legs. 56
4670473 1972
7
The health and economic burden of podoconiosis in Ethiopia. 61
32055853 2020
8
The impact of leprosy, podoconiosis and lymphatic filariasis on family quality of life: A qualitative study in Northwest Ethiopia. 61
32155158 2020
9
Quantifying the socio-economic impact of leg lymphoedema on patient caregivers in a lymphatic filariasis and podoconiosis co-endemic district of Ethiopia. 61
32126081 2020
10
The design and development of a multicentric protocol to investigate the impact of adjunctive doxycycline on the management of peripheral lymphoedema caused by lymphatic filariasis and podoconiosis. 61
32228663 2020
11
With Bare Feet in the Soil: Podoconiosis, a Neglected Cause of Tropical Lymphoedema. 61
32101870 2020
12
Epidemiology of podoconiosis in Ethiopia: a systematic review and meta-analysis protocol. 61
31915168 2020
13
Mapping the global distribution of podoconiosis: Applying an evidence consensus approach. 61
31790408 2019
14
Gender-related factors affecting health seeking for neglected tropical diseases: findings from a qualitative study in Ethiopia. 61
31830026 2019
15
Intra-Rater Reliability and Agreement of the Indurometer When Used to Assess Mid-Calf Tissue Compressibility Among People Affected by Moderate to Severe Lymphedema in Bangladesh and Ethiopia. 61
31859599 2019
16
Dr E W Price, the discoverer of podoconiosis. 61
31735101 2019
17
Picturing health: podoconiosis-stepping out of neglect. 61
32534625 2019
18
Comparison of Staging Systems to Assess Lymphedema Caused by Cancer Therapies, Lymphatic Filariasis, and Podoconiosis. 61
30789319 2019
19
Cost-effectiveness and social outcomes of a community-based treatment for podoconiosis lymphoedema in the East Gojjam zone, Ethiopia. 61
31644556 2019
20
An Enhanced Self-Care Protocol for People Affected by Moderate to Severe Lymphedema. 61
31487887 2019
21
The impact of acute adenolymphangitis in podoconiosis on caregivers: A case study in Wayu Tuka woreda, Oromia, Western Ethiopia. 'If she was healthy, I would be free.' 61
31283763 2019
22
Depressive Symptoms Amongst People with Podoconiosis and Lower Limb Lymphoedema of Other Cause in Cameroon: A Cross-Sectional Study. 61
31323942 2019
23
Prevalence surveys for podoconiosis and other neglected skin diseases: time for an integrated approach. 61
30926302 2019
24
Geographical distribution and prevalence of podoconiosis in Rwanda: a cross-sectional country-wide survey. 61
30926303 2019
25
Regional bedrock geochemistry associated with podoconiosis evaluated by multivariate analysis. 61
30187152 2019
26
Community based cross sectional study of podoconiosis and associated factors in Dano district, Central Ethiopia. 61
30689654 2019
27
Applying Mental Model Methods to Characterize Understanding of Gene-Environment Influences: The Case of Podoconiosis in Ethiopia. 61
30853753 2019
28
Podoconiosis today: challenges and opportunities. 61
30137612 2018
29
Lymphoedema management in podoconiosis. 61
30103994 2018
30
Lymphoedema management in podoconiosis - Authors reply. 61
30103995 2018
31
Podoconiosis pathogenesis: renewed use of an historical archive. 61
30239941 2018
32
Podoconiosis research to implementation: a call for global action. 61
30103988 2018
33
Rural youths' understanding of gene x environmental contributors to heritable health conditions: The case of podoconiosis in Ethiopia. 61
30212466 2018
34
Community Involvement in the Care of Persons Affected by Podoconiosis-A Lesson for Other Skin NTDs. 61
30274483 2018
35
Podoconiosis: Nonfilarial endemic elephantiasis. 61
29371058 2018
36
Integrated care programme for acute episodes in patients with podoconiosis. 61
29773515 2018
37
Integrated morbidity mapping of lymphatic filariasis and podoconiosis cases in 20 co-endemic districts of Ethiopia. 61
29965963 2018
38
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia. 61
30101228 2018
39
Lymphoedema management to prevent acute dermatolymphangioadenitis in podoconiosis in northern Ethiopia (GoLBeT): a pragmatic randomised controlled trial. 61
29773516 2018
40
Study of lymphoedema of non-filarial origin in the northwest region of Cameroon: spatial distribution, profiling of cases and socio-economic aspects of podoconiosis. 61
29771349 2018
41
A Human Right to Shoes? Establishing Rights and Duties in the Prevention and Treatment of Podoconiosis. 61
30008552 2018
42
A Comparative Analysis of Economic Cost of Podoconiosis and Leprosy on Affected Households in the Northwest Region of Cameroon. 61
29460727 2018
43
Global epidemiology of podoconiosis: A systematic review. 61
29494642 2018
44
Involvement of Hookworm Co-Infection in the Pathogenesis and Progression of Podoconiosis: Possible Immunological Mechanism. 61
30274434 2018
45
A comparison between paper-based and m-Health tools for collating and reporting clinical cases of lymphatic filariasis and podoconiosis in Ethiopia. 61
30505847 2018
46
'I should not feed such a weak woman'. Intimate partner violence among women living with podoconiosis: A qualitative study in northern Ethiopia. 61
30521548 2018
47
Mapping the geographical distribution of podoconiosis in Cameroon using parasitological, serological, and clinical evidence to exclude other causes of lymphedema. 61
29324858 2018
48
Predicted distribution and burden of podoconiosis in Cameroon. 61
29946487 2018
49
A randomized controlled trial to evaluate the effect of a new skincare regimen on skin barrier function in those with podoconiosis in Ethiopia. 61
28374907 2017
50
Washing with water and glycerine improves skin barrier function and quality of life in patients with podoconiosis. 61
29192997 2017

Variations for Podoconiosis

Expression for Podoconiosis

Search GEO for disease gene expression data for Podoconiosis.

Pathways for Podoconiosis

Pathways related to Podoconiosis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.11 HLA-DQB1 HLA-DQA2 HLA-DQA1
2
Show member pathways
12.07 HLA-DQB1 HLA-DQA2 HLA-DQA1
3 12.05 HLA-DQB1 HLA-DQA2 HLA-DQA1
4
Show member pathways
11.98 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 11.94 HLA-DQB1 HLA-DQA2 HLA-DQA1
6
Show member pathways
11.91 HLA-DQB1 HLA-DQA2 HLA-DQA1
7 11.84 HLA-DQB1 HLA-DQA2 HLA-DQA1
8 11.78 HLA-DQB1 HLA-DQA2 HLA-DQA1
9 11.62 HLA-DQB1 HLA-DQA2 HLA-DQA1
10
Show member pathways
11.62 HLA-DQB1 HLA-DQA2 HLA-DQA1
11 11.56 HLA-DQB1 HLA-DQA2 HLA-DQA1
12 11.49 HLA-DQB1 HLA-DQA2 HLA-DQA1
13 11.42 HLA-DQB1 HLA-DQA2 HLA-DQA1
14 11.3 HLA-DQB1 HLA-DQA2 HLA-DQA1
15 10.98 HLA-DQB1 HLA-DQA2 HLA-DQA1
16
Show member pathways
10.76 HLA-DQB1 HLA-DQA2 HLA-DQA1

GO Terms for Podoconiosis

Cellular components related to Podoconiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.61 HLA-DQB1 HLA-DQA2 HLA-DQA1
2 trans-Golgi network membrane GO:0032588 9.58 HLA-DQB1 HLA-DQA2 HLA-DQA1
3 endocytic vesicle membrane GO:0030666 9.54 HLA-DQB1 HLA-DQA2 HLA-DQA1
4 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 transport vesicle membrane GO:0030658 9.43 HLA-DQB1 HLA-DQA2 HLA-DQA1
6 clathrin-coated endocytic vesicle membrane GO:0030669 9.33 HLA-DQB1 HLA-DQA2 HLA-DQA1
7 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.13 HLA-DQB1 HLA-DQA2 HLA-DQA1
8 MHC class II protein complex GO:0042613 8.8 HLA-DQB1 HLA-DQA2 HLA-DQA1

Biological processes related to Podoconiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.5 HLA-DQB1 HLA-DQA2 HLA-DQA1
2 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.33 HLA-DQB1 HLA-DQA2 HLA-DQA1
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DQA2 HLA-DQA1
4 interferon-gamma-mediated signaling pathway GO:0060333 9.13 HLA-DQB1 HLA-DQA2 HLA-DQA1
5 antigen processing and presentation GO:0019882 8.8 HLA-DQB1 HLA-DQA2 HLA-DQA1

Molecular functions related to Podoconiosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DQB1 HLA-DQA1
2 MHC class II receptor activity GO:0032395 8.8 HLA-DQB1 HLA-DQA2 HLA-DQA1

Sources for Podoconiosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....